PT2102331E - Vacina antitumoral derivada de células cd4+ normais modificadas quimicamente - Google Patents
Vacina antitumoral derivada de células cd4+ normais modificadas quimicamente Download PDFInfo
- Publication number
- PT2102331E PT2102331E PT08701232T PT08701232T PT2102331E PT 2102331 E PT2102331 E PT 2102331E PT 08701232 T PT08701232 T PT 08701232T PT 08701232 T PT08701232 T PT 08701232T PT 2102331 E PT2102331 E PT 2102331E
- Authority
- PT
- Portugal
- Prior art keywords
- cells
- lymphocytes
- antigens
- cancer
- cell
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 19
- 230000000259 anti-tumor effect Effects 0.000 title abstract description 7
- 210000004698 lymphocyte Anatomy 0.000 claims abstract description 158
- 210000004027 cell Anatomy 0.000 claims abstract description 150
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 103
- 108091007433 antigens Proteins 0.000 claims abstract description 86
- 102000036639 antigens Human genes 0.000 claims abstract description 86
- 239000000427 antigen Substances 0.000 claims abstract description 84
- 210000004443 dendritic cell Anatomy 0.000 claims abstract description 54
- 230000014509 gene expression Effects 0.000 claims abstract description 54
- 201000011510 cancer Diseases 0.000 claims abstract description 51
- 239000000203 mixture Substances 0.000 claims abstract description 47
- 238000011282 treatment Methods 0.000 claims abstract description 30
- 230000035755 proliferation Effects 0.000 claims abstract description 26
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims abstract description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 20
- 230000028993 immune response Effects 0.000 claims abstract description 17
- 230000002062 proliferating effect Effects 0.000 claims abstract description 16
- 210000001550 testis Anatomy 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 14
- 230000004913 activation Effects 0.000 claims abstract description 11
- 230000001939 inductive effect Effects 0.000 claims abstract description 10
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims abstract description 10
- 238000009169 immunotherapy Methods 0.000 claims abstract description 9
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 5
- 230000035131 DNA demethylation Effects 0.000 claims abstract description 3
- 241000124008 Mammalia Species 0.000 claims abstract description 3
- 230000000069 prophylactic effect Effects 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 44
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 claims description 38
- 230000001472 cytotoxic effect Effects 0.000 claims description 29
- 231100000433 cytotoxic Toxicity 0.000 claims description 25
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 19
- 230000000638 stimulation Effects 0.000 claims description 12
- 230000002381 testicular Effects 0.000 claims description 11
- 230000030741 antigen processing and presentation Effects 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 230000017858 demethylation Effects 0.000 claims description 8
- 238000010520 demethylation reaction Methods 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 230000006195 histone acetylation Effects 0.000 claims description 4
- 230000007067 DNA methylation Effects 0.000 claims description 3
- 230000003213 activating effect Effects 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 230000008105 immune reaction Effects 0.000 claims 2
- 230000006197 histone deacetylation Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 description 35
- 230000006698 induction Effects 0.000 description 20
- 239000002609 medium Substances 0.000 description 20
- 108090000623 proteins and genes Proteins 0.000 description 20
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 16
- 108010002350 Interleukin-2 Proteins 0.000 description 15
- 102000000588 Interleukin-2 Human genes 0.000 description 15
- 108050008953 Melanoma-associated antigen Proteins 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 13
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 13
- 102000000440 Melanoma-associated antigen Human genes 0.000 description 13
- 230000001464 adherent effect Effects 0.000 description 13
- 230000004044 response Effects 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 230000015654 memory Effects 0.000 description 12
- 238000012737 microarray-based gene expression Methods 0.000 description 11
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 11
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 10
- 210000002966 serum Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 9
- 210000001616 monocyte Anatomy 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000006285 cell suspension Substances 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 102100037850 Interferon gamma Human genes 0.000 description 7
- 108010074328 Interferon-gamma Proteins 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 201000001441 melanoma Diseases 0.000 description 7
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 6
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 description 6
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000016911 Deoxyribonucleases Human genes 0.000 description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 5
- 102100033467 L-selectin Human genes 0.000 description 5
- 230000014102 antigen processing and presentation of exogenous peptide antigen via MHC class I Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 4
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 4
- 101000894428 Homo sapiens Transcriptional repressor CTCFL Proteins 0.000 description 4
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 230000005867 T cell response Effects 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 229940030156 cell vaccine Drugs 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 210000000987 immune system Anatomy 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 238000010240 RT-PCR analysis Methods 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010968 computed tomography angiography Methods 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000012595 freezing medium Substances 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 description 3
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 3
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 3
- 230000001024 immunotherapeutic effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- SSOORFWOBGFTHL-OTEJMHTDSA-N (4S)-5-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[2-[(2S)-2-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-6-amino-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-5-carbamimidamido-1-[[(2S)-5-carbamimidamido-1-[[(1S)-4-carbamimidamido-1-carboxybutyl]amino]-1-oxopentan-2-yl]amino]-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-1-oxohexan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-2-oxoethyl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-[[(2S)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-methylbutanoyl]amino]propanoyl]amino]-5-oxopentanoic acid Chemical compound CC[C@H](C)[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](N)CCCCN)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SSOORFWOBGFTHL-OTEJMHTDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000043131 MHC class II family Human genes 0.000 description 2
- 108091054438 MHC class II family Proteins 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- 102000006382 Ribonucleases Human genes 0.000 description 2
- 108010083644 Ribonucleases Proteins 0.000 description 2
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000961 alloantigen Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 210000000172 cytosol Anatomy 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940047122 interleukins Drugs 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- YEENEYXBHNNNGV-XEHWZWQGSA-M sodium;3-acetamido-5-[acetyl(methyl)amino]-2,4,6-triiodobenzoate;(2r,3r,4s,5s,6r)-2-[(2r,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound [Na+].CC(=O)N(C)C1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I.O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 YEENEYXBHNNNGV-XEHWZWQGSA-M 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 229930185603 trichostatin Natural products 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 230000037455 tumor specific immune response Effects 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- IDYKCXHJJGMAEV-RRKCRQDMSA-N 4-amino-5-fluoro-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(F)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 IDYKCXHJJGMAEV-RRKCRQDMSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 240000002989 Euphorbia neriifolia Species 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 1
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 1
- 101001005728 Homo sapiens Melanoma-associated antigen 1 Proteins 0.000 description 1
- 101001005719 Homo sapiens Melanoma-associated antigen 3 Proteins 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108091054437 MHC class I family Proteins 0.000 description 1
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 1
- 102100025082 Melanoma-associated antigen 3 Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 208000004605 Persistent Truncus Arteriosus Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241001337451 Polyblastus cancer Species 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000037258 Truncus arteriosus Diseases 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical class O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000015961 delipidation Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 102000057056 human CTCFL Human genes 0.000 description 1
- 102000045753 human MAGEA1 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229940075628 hypomethylating agent Drugs 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000007420 reactivation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- RPQZTTQVRYEKCR-WCTZXXKLSA-N zebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=CC=C1 RPQZTTQVRYEKCR-WCTZXXKLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
- A61K40/24—Antigen-presenting cells [APC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/06—Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
- C12N2502/1121—Dendritic cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0700058.1A GB0700058D0 (en) | 2007-01-03 | 2007-01-03 | Anti-tumor vaccine based on normal cells |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2102331E true PT2102331E (pt) | 2011-12-19 |
Family
ID=37759205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT08701232T PT2102331E (pt) | 2007-01-03 | 2008-01-03 | Vacina antitumoral derivada de células cd4+ normais modificadas quimicamente |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10023839B2 (enExample) |
| EP (1) | EP2102331B1 (enExample) |
| JP (1) | JP5452231B2 (enExample) |
| AT (1) | ATE522600T1 (enExample) |
| AU (1) | AU2008203730B2 (enExample) |
| CY (1) | CY1112668T1 (enExample) |
| DK (1) | DK2102331T3 (enExample) |
| ES (1) | ES2372713T3 (enExample) |
| GB (1) | GB0700058D0 (enExample) |
| HR (1) | HRP20110899T1 (enExample) |
| PL (1) | PL2102331T3 (enExample) |
| PT (1) | PT2102331E (enExample) |
| SI (1) | SI2102331T1 (enExample) |
| WO (1) | WO2008081035A1 (enExample) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA011421B1 (ru) * | 2008-08-26 | 2009-02-27 | Петр Генриевич ЛОХОВ | Способ получения противоопухолевой вакцины |
| US8666674B2 (en) | 2009-07-28 | 2014-03-04 | Promising Future, Llc | Pairing processes for preparing reactive cytotoxic T cells |
| US8586359B2 (en) * | 2009-07-28 | 2013-11-19 | Promising Furture, LLC | Compositions and methods of preparing alloreactive cytotoxic T cells |
| EP2494038B1 (en) * | 2009-10-27 | 2019-06-26 | Immunicum AB | Method for proliferation of antigen-specific t cells |
| GB201013443D0 (en) | 2010-08-11 | 2010-09-22 | Cytovac As | Compositions and methods for producing dendritic cells |
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| EA201792649A1 (ru) | 2015-05-28 | 2018-06-29 | Кайт Фарма, Инк. | Способы кондиционирования пациентов для t-клеточной терапии |
| EA201792642A1 (ru) | 2015-05-28 | 2018-10-31 | Кайт Фарма, Инк. | Способы диагностики для т-клеточной терапии |
| KR20180063320A (ko) | 2015-10-20 | 2018-06-11 | 카이트 파마 인코포레이티드 | T 세포 요법을 위한 t 세포를 제조하는 방법 |
| PE20200400A1 (es) | 2016-04-01 | 2020-02-26 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| TWI691596B (zh) | 2016-04-01 | 2020-04-21 | 美商凱特製藥公司 | 嵌合抗原和ｔ細胞受體及使用方法 |
| TWI761831B (zh) | 2016-04-01 | 2022-04-21 | 美商凱特製藥公司 | 嵌合抗原受體（ｃａｒ）和ｔ細胞受體（ｔｃｒ）及彼等之用途 |
| ES2900233T3 (es) | 2017-02-14 | 2022-03-16 | Kite Pharma Inc | Moléculas que se unen a CD70 y métodos de uso de las mismas |
| TW201837175A (zh) | 2017-03-13 | 2018-10-16 | 美商凱特製藥公司 | 用於黑色素瘤之嵌合抗原受體及其用途 |
| CA3054443A1 (en) | 2017-04-01 | 2018-10-14 | Avm Biotechnology, Llc | Replacement of cytotoxic preconditioning before cellular immunotherapy |
| TW201902493A (zh) | 2017-04-03 | 2019-01-16 | 美商凱特製藥公司 | 使用併入最佳化多功能t細胞之嵌合受體t細胞之治療 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| TWI862477B (zh) | 2017-05-26 | 2024-11-21 | 美商凱特製藥公司 | 製備和使用胚胎間充質先驅細胞的方法 |
| EP3681531A1 (en) | 2017-09-15 | 2020-07-22 | Kite Pharma, Inc. | Methods and systems for performing a patient-specific immunotherapy procedure with chain-of-custody and chain-of-identity biological sample tracking |
| WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
| CN111479613A (zh) | 2017-10-18 | 2020-07-31 | 凯德药业股份有限公司 | 施用嵌合抗原受体免疫疗法的方法 |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| CA3087481A1 (en) | 2018-01-15 | 2019-07-18 | Pfizer Inc. | Methods of administering chimeric antigen receptor immunotherapy in combination with 4-1bb agonist |
| WO2019152957A1 (en) | 2018-02-02 | 2019-08-08 | Arizona Board Of Regents On Behalf Of Arizona State University | Dna-chimeric antigen receptor t cells for immunotherapy |
| US20210040449A1 (en) | 2018-02-16 | 2021-02-11 | Kite Pharma, Inc. | Modified pluripotent stem cells and methods of making and use |
| IL310416B1 (en) | 2018-04-12 | 2025-12-01 | Kite Pharma Inc | Chimeric T-cell receptor therapy using tumor microenvironmental characteristics |
| WO2019232510A1 (en) | 2018-06-01 | 2019-12-05 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| WO2019243888A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma Eu B.V. | Compositions and methods for making engineered t cells |
| CA3107938C (en) | 2018-08-02 | 2024-04-30 | Kite Pharma, Inc. | Chimeric antigen receptor therapy t cell expansion kinetics and uses thereof |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| CN120025452A (zh) | 2018-12-12 | 2025-05-23 | 凯德药业股份有限公司 | 嵌合抗原和t细胞受体及使用的方法 |
| EP3953454A1 (en) * | 2019-04-12 | 2022-02-16 | CytoVac A/S | Method for preparation of cancer/testis antigen-specific t-cells |
| JP2022532865A (ja) | 2019-05-03 | 2022-07-20 | カイト ファーマ インコーポレイテッド | キメラ抗原受容体免疫療法の投与方法 |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| US20210062150A1 (en) | 2019-09-03 | 2021-03-04 | Allogene Therapeutics, Inc. | Methods of preparing t cells for t cell therapy |
| US20230293530A1 (en) | 2020-06-24 | 2023-09-21 | Yeda Research And Development Co. Ltd. | Agents for sensitizing solid tumors to treatment |
| US20220047677A1 (en) | 2020-08-14 | 2022-02-17 | Kite Pharma, Inc. | Immune cell function |
| EP4204545A2 (en) | 2020-08-25 | 2023-07-05 | Kite Pharma, Inc. | T cells with improved functionality |
| EP4237854A1 (en) | 2020-10-28 | 2023-09-06 | Kite Pharma, Inc. | Flow cytometric method for characterization of t-cell impurities |
| WO2022140159A1 (en) | 2020-12-24 | 2022-06-30 | Kite Pharma, Inc. | Prostate cancer chimeric antigen receptors |
| CN116917737A (zh) | 2021-01-10 | 2023-10-20 | 凯德药业股份有限公司 | T细胞疗法 |
| WO2022157288A1 (en) | 2021-01-21 | 2022-07-28 | Cytovac A/S | Method for t-cell expansion and related medical applications |
| TW202241469A (zh) | 2021-02-20 | 2022-11-01 | 美商凱特製藥公司 | 免疫療法 |
| JP7690597B2 (ja) | 2021-03-11 | 2025-06-10 | カイト ファーマ インコーポレイテッド | 免疫細胞機能の改善 |
| JP7688723B2 (ja) | 2021-04-16 | 2025-06-04 | カイト ファーマ インコーポレイテッド | Ｔａｃｉ／ｂｃｍａ二重結合分子 |
| WO2022221126A1 (en) | 2021-04-16 | 2022-10-20 | Kite Pharma, Inc. | Methods and systems for scheduling a patient-specific immunotherapy procedure |
| EP4337227A2 (en) | 2021-05-14 | 2024-03-20 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| US12331315B2 (en) | 2021-05-24 | 2025-06-17 | Kite Pharma, Inc. | Chimeric antigen receptor |
| EP4352102A1 (en) | 2021-06-08 | 2024-04-17 | Kite Pharma, Inc. | Gpc3 binding molecules |
| WO2022269019A1 (en) | 2021-06-25 | 2022-12-29 | Cytovac A/S | Method for preparation of cytotoxic t lymphocytes with broad tumour-specific reactivity and characteristics of early differentiation cells |
| EP4363558A1 (en) | 2021-07-01 | 2024-05-08 | Kite Pharma, Inc. | Closed-system and method for autologous and allogeneic cell therapy manufacturing |
| US20230103457A1 (en) | 2021-07-02 | 2023-04-06 | Kite Pharma, Inc. | Method for identifying variants in gene products from gene constructs used in cell therapy applications |
| EP4376876A1 (en) | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| EP4377694A1 (en) | 2021-07-30 | 2024-06-05 | Kite Pharma, Inc. | Monitoring and management of cell therapy-induced toxicities |
| IL311981A (en) | 2021-10-18 | 2024-06-01 | Kite Pharma Inc | Signaling domains for chimeric antigen receptors |
| KR20240144434A (ko) | 2022-02-15 | 2024-10-02 | 카이트 파마 인코포레이티드 | 면역요법으로 인한 유해사례 예측 |
| WO2023247324A1 (en) | 2022-06-24 | 2023-12-28 | Cytovac A/S | Novel combination treatment with adoptive cellular therapy |
| EP4577234A1 (en) | 2022-08-26 | 2025-07-02 | Kite Pharma, Inc. | Improving immune cell function |
| CN119997962A (zh) | 2022-10-28 | 2025-05-13 | 凯德药业股份有限公司 | 改善免疫疗法的功效和持久应答 |
| WO2024092227A1 (en) | 2022-10-28 | 2024-05-02 | Kite Pharma, Inc. | Factors for optimizing immunotherapy |
| KR20250162836A (ko) | 2023-03-17 | 2025-11-19 | 카이트 파마 인코포레이티드 | 종양 미세환경이 면역요법의 효능에 미치는 영향 |
| US20250161361A1 (en) | 2023-11-01 | 2025-05-22 | Kite Pharma, Inc. | Factors for optimizing immunotherapy efficacy |
| WO2025174963A1 (en) | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| WO2025188561A1 (en) | 2024-03-04 | 2025-09-12 | Kite Pharma, Inc. | Predictive markers for immunotherapy |
| US20250388680A1 (en) | 2024-05-03 | 2025-12-25 | Kite Pharma, Inc. | Chimeric receptors and methods of use thereof |
| WO2025250819A1 (en) | 2024-05-31 | 2025-12-04 | Kite Pharma, Inc. | Tricistronic constructs for anti-gpc3 car |
| WO2026015457A1 (en) | 2024-07-08 | 2026-01-15 | Kite Pharma, Inc. | Systems and methods for applying mechanical force to living cells to generate a phenotypic response |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003012085A1 (en) * | 2001-07-30 | 2003-02-13 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Antigen presenting cells, method for their preparation and their use for cancer vaccines |
-
2007
- 2007-01-03 GB GBGB0700058.1A patent/GB0700058D0/en not_active Ceased
-
2008
- 2008-01-03 PL PL08701232T patent/PL2102331T3/pl unknown
- 2008-01-03 JP JP2009544412A patent/JP5452231B2/ja not_active Expired - Fee Related
- 2008-01-03 EP EP08701232A patent/EP2102331B1/en active Active
- 2008-01-03 AU AU2008203730A patent/AU2008203730B2/en not_active Ceased
- 2008-01-03 PT PT08701232T patent/PT2102331E/pt unknown
- 2008-01-03 WO PCT/EP2008/050050 patent/WO2008081035A1/en not_active Ceased
- 2008-01-03 SI SI200830447T patent/SI2102331T1/sl unknown
- 2008-01-03 HR HR20110899T patent/HRP20110899T1/hr unknown
- 2008-01-03 ES ES08701232T patent/ES2372713T3/es active Active
- 2008-01-03 DK DK08701232.4T patent/DK2102331T3/da active
- 2008-01-03 AT AT08701232T patent/ATE522600T1/de active
- 2008-01-03 US US12/522,048 patent/US10023839B2/en active Active
-
2011
- 2011-11-17 CY CY20111101112T patent/CY1112668T1/el unknown
-
2017
- 2017-09-18 US US15/707,474 patent/US20180036397A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2372713T3 (es) | 2012-01-25 |
| US20180036397A1 (en) | 2018-02-08 |
| GB0700058D0 (en) | 2007-02-07 |
| US10023839B2 (en) | 2018-07-17 |
| DK2102331T3 (da) | 2011-10-17 |
| AU2008203730A1 (en) | 2008-07-10 |
| PL2102331T3 (pl) | 2012-01-31 |
| EP2102331A1 (en) | 2009-09-23 |
| SI2102331T1 (sl) | 2012-01-31 |
| US20100092498A1 (en) | 2010-04-15 |
| CY1112668T1 (el) | 2016-02-10 |
| JP5452231B2 (ja) | 2014-03-26 |
| JP2010514455A (ja) | 2010-05-06 |
| HRP20110899T1 (hr) | 2011-12-31 |
| AU2008203730B2 (en) | 2013-11-07 |
| WO2008081035A1 (en) | 2008-07-10 |
| ATE522600T1 (de) | 2011-09-15 |
| EP2102331B1 (en) | 2011-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10023839B2 (en) | Anti-tumour vaccine derived from normal cells | |
| Escors | Tumour immunogenicity, antigen presentation, and immunological barriers in cancer immunotherapy | |
| Dashti et al. | Dendritic cell based immunotherapy using tumor stem cells mediates potent antitumor immune responses | |
| von Euw et al. | A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10-1082 promoter genotype as predictor of disease progression | |
| Trefzer et al. | Vaccination with hybrids of tumor and dendritic cells induces tumor‐specific T‐cell and clinical responses in melanoma stage III and IV patients | |
| TW202108761A (zh) | T細胞製備組合物及方法 | |
| EP3255143A2 (en) | Enhancing the t-cells stimulatory capacity of human antigen presenting cells and their use in vaccination | |
| EP2603582B1 (en) | Compositions and methods for producing dendritic cells | |
| Tsai et al. | In vitro immunization and expansion of antigen-specific cytotoxic T lymphocytes for adoptive immunotherapy using peptide-pulsed dendritic cells | |
| Inzkirweli et al. | Antigen loading of dendritic cells with apoptotic tumor cell-preparations is superior to that using necrotic cells or tumor lysates | |
| Abdel-Wahab et al. | Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses | |
| Gang et al. | Efficient induction of specific cytotoxic T lymphocytes against gastric adenocarcinoma by a survivin peptide | |
| Vichchatorn et al. | Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme | |
| Wang et al. | Effect of dendritic cell vaccine against a tongue squamous cell cancer cell line (Tca8113) in vivo and in vitro | |
| WO2023092153A2 (en) | Methods and compositions targeting nucleus accumbens-associated protein-1 for treatment of autoimmune disorders and cancers | |
| JP7390740B2 (ja) | 腫瘍の治療及び／又は予防のための組成物 | |
| ES2791410T3 (es) | Uso de composiciones inmunomoduladoras eficaces para el tratamiento inmunoterápico de pacientes que padecen leucemias mielógenas | |
| Abe et al. | Targeted cancer therapy by dendritic cell vaccine | |
| US20230381291A1 (en) | Tumor-associated peptides and uses thereof | |
| HK40071072B (zh) | T细胞制备组合物和方法 | |
| Gunther et al. | Novel Small-Molecule TOP2 Catalytic Inhibitor | |
| Paglia et al. | Presentation of tumor antigens: The role of dendritic cells | |
| Kibbi | T Cell Calcium Flux And Clonal Proliferation Report On Antigen-Specific Myeloid Cell Encounters | |
| Dorsky | Regulation of Melanoma Epitope-specific Cytolytic T Lymphocyte Response by Immature and Activated Dendritic Cells, in Vitro1 | |
| BRPI0803471A2 (pt) | vacina de células hìbridas dendrìticas-tumorais para o tratamento de melanoma |